Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 11/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24844853 | 1.00 | TBXAS1 (0.48) | TBXAS1CYP19A1CYP11B1CYP11B2CYP4F2 | |
| SCHEMBL24844866 | 1.00 | TBXAS1 (0.48) | TBXAS1CYP19A1CYP11B1CYP11B2CYP4F2 | |
| SCHEMBL24845187 | 0.86 | TBXAS1 (0.49) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL30110512 | 0.86 | TBXAS1 (0.49) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24844859 | 0.86 | TBXAS1 (0.49) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24845630 | 0.86 | TBXAS1 (0.48) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24844868 | 0.86 | TBXAS1 (0.48) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24845013 | 0.86 | TBXAS1 (0.48) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24844927 | 0.85 | TBXAS1 (0.46) | TBXAS1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL24844849 | 0.82 | CYP4F2 (0.46) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336638-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | ZHUGE, Guoqin (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-115557898-B | Imidazole compound, intermediate and application thereof | 诸葛国琴 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| CN-115557898-A | Imidazole compound, intermediate and application thereof | 诸葛国琴 | 2023-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336638-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | PINK1, TFPI, PLAT | TBXAS1 226/4885CYP19A1 1775/4885CYP11B1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.